Related Experiment Videos

Prospective, randomized study of the efficacy of Mepitel on children with partial-thickness scalds

C S Gotschall1, M I Morrison, M R Eichelberger

  • 1Emergency Trauma Services, Children's National Medical Center, Washington, DC 20010-2970, USA.

Insights

Mepitel significantly speeds healing and reduces pain for children with partial-thickness scald burns compared to silver sulfadiazine. This innovative treatment also lowers healthcare costs without increasing infection rates.

Area of Science:

  • Pediatric Burn Care
  • Wound Management
  • Clinical Trials

Background:

  • Partial-thickness scald burns are common in children.
  • Current treatments like silver sulfadiazine have limitations.
  • Optimizing healing and patient comfort is crucial.

Purpose of the Study:

  • To compare the efficacy of Mepitel versus silver sulfadiazine in treating pediatric partial-thickness scald burns.
  • To evaluate differences in healing time, pain, infection, and resource utilization.

Main Methods:

  • Randomized clinical trial involving children with <15% total body surface area scald burns.
  • Treatment groups: Mepitel vs. silver sulfadiazine.
  • Outcome measures: time to healing, pain, infection, resource use; analyzed with t-tests, chi-square, and Kaplan-Meier curves.

Main Results:

  • Mepitel group showed significantly faster wound healing (p < 0.001).
  • Reduced eschar formation (p < 0.05) and less pain during dressing changes (p < 0.05) in the Mepitel group.
  • Significantly lower mean daily hospital charges ($1937 vs $2316; p = 0.025) and dressing/narcotic costs with Mepitel.
  • No significant difference in wound infection rates between groups.

Conclusions:

  • Mepitel is a superior treatment for pediatric partial-thickness scald burns, offering faster healing and reduced pain.
  • Mepitel provides significant cost savings in healthcare resource utilization.
  • The use of Mepitel represents a significant advancement in pediatric burn wound care.

Related Concept Videos